http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20140125606-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_56820bbb13a42311271e147869a36d30 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-585 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0091 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| filingDate | 2013-04-19^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_59c729545a2291a637112423468bfc1b |
| publicationDate | 2014-10-29^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20140125606-A |
| titleOfInvention | Pharmaceutical composition for preventing or treating bladder cancer comprising inducer or activator of BTG2 and screening method thereof |
| abstract | The present invention relates to a pharmaceutical composition comprising a B cell translocation gene 2 (BTG2) expression promoter or a BTG2 activator as an active ingredient for the prevention or treatment of bladder cancer; and to a screening method of the pharmaceutical composition. The present invention provides a screening method of a therapeutic agent for bladder cancer, which comprises the steps of: treating bladder cancer cell lines with test substances; and selecting a test substance which has the increased expression level or activation level of the protein BTG2 in comparison with a control group. Furthermore, the present invention provides a BTG2 marker detection method for diagnosis of bladder cancer, which comprises the steps of: measuring the mRNA expression level of the gene BTG2 or the expression level of protein coded by the gene from a sample obtained from a bladder cancer patient; and making a comparison with a sample obtained from a normal control group. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20160112165-A |
| priorityDate | 2013-04-19^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 276 of 276.